Efficacy and safety of epicutaneous immunotherapy for severe milk allergy
Phase 2
- Conditions
- Food allergy
- Registration Number
- JPRN-UMIN000024564
- Lead Sponsor
- ational Hospital Organization Mie National Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
Not provided
Exclusion Criteria
1)patients whose intake levels of milk changed within 3 months of the trial 2)patients who had milk oral immunotherapy within 6 months 3) patients who are on other immunotherapy 4)patients who have heart, liver and kidney diseases 5)patients with ncontrolled asthma or atopic dermatitis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of the subjects who tolerate more than 3 ml of milk (total dose) at oral milk challenge after the treatment for 24 weeks
- Secondary Outcome Measures
Name Time Method 1.Safety: local reaction, systemic immediate-type allergic reaction and other 2.Prick test 3.Specific IgE and IgG4